Weight-loss treatment options are expanding beyond the familiar weekly injection. Here is a dated U.S. update on recent FDA approvals and two treatments still in development. Approval, availability at a pharmacy, and insurance coverage are separate questions.
myleafrx drug update · Information checked September 22, 2026
Recently approved: what has changed?
Foundayo: a new daily oral option
The FDA approved Foundayo (orforglipron) on April 1, 2026. This daily GLP-1 tablet is indicated for weight reduction and long-term maintenance in adults with obesity, or overweight with a weight-related condition, alongside diet and activity changes. It does not require an empty stomach. It has important risks, including gastrointestinal effects and a boxed thyroid-tumor warning, and should not be combined with another GLP-1 medicine. Read the FDA’s Foundayo approval and safety summary.
Wegovy tablets: semaglutide in pill form
The FDA approved Wegovy tablets on December 22, 2025, bringing an oral semaglutide option into the 2026 treatment landscape. The weight-management indication is for eligible adults. The tablets have specific morning, empty-stomach instructions; a tablet and an injection are not interchangeable dose for dose. FDA approval letter; current prescribing information checked for this article.
Wegovy HD: an additional injection option
On March 19, 2026, the FDA approved Wegovy HD (semaglutide 7.2 mg) for weight reduction and long-term maintenance in certain adults. This is a higher-dose option, not a starting dose or a reason to increase an existing prescription yourself. The FDA highlighted gastrointestinal effects, more frequent altered skin sensation at the higher dose, and the thyroid-tumor boxed warning. A prescriber should decide whether it is appropriate. FDA announcement.
Still in development: promising does not mean approved
Retatrutide
Retatrutide is not FDA-approved as of this update. Lilly is studying this weekly injection, which targets GIP, GLP-1, and glucagon receptors, in Phase 3 trials. The company reported additional trial results in 2026, but no public launch date should be treated as certain. Lilly states that it is available only through its clinical trials. Lilly’s development-status explanation.
CagriSema
CagriSema remains investigational. It combines cagrilintide and semaglutide in a weekly injection. Novo Nordisk announced new Phase 3 topline results on September 21, 2026. The company says it filed for U.S. weight-management approval in December 2025 and expects an FDA decision in the fourth quarter of 2026. That is a company expectation, not an approval or guaranteed launch. Novo Nordisk’s September 21 update.
How to read a new-drug headline
- Check the status: an FDA approval is different from a trial result, a submitted application, or an approval in another country.
- Check the study: participant health, dose, follow-up time, and how discontinued treatment is counted can change the result. Percentages from separate trials are not a reliable personal ranking.
- Check the practical details: ask about the exact product, follow-up, pharmacy supply, and ongoing out-of-pocket cost.
Products advertised online as “research peptides” are not a shortcut to an approved prescription. The FDA warns about unapproved GLP-1 products, including retatrutide and cagrilintide.
What to do with this information
Bring questions to your clinician before changing treatment. Our GLP-1 medication guide covers the basics, and our cost and coverage guide explains how to compare payment options.
You can search myleafrx for current prescription prices after you have the exact prescription details. A recently approved medicine may not yet appear in the search. Call 1-833-941-1140 if you need help; no price, stock, coverage, or savings is guaranteed.
Educational information, not a treatment recommendation. myleafrx does not prescribe medicines. This article is a September 22, 2026 snapshot; approval status and availability can change. Sources are linked throughout.